Exploring the Implications of New Data on Established and Emerging Therapies for Advanced RCC: How Will Clinical Practice Be Affected?

Activity Description & Educational Objectives

In this activity, experts in renal cell carcinoma (RCC) discuss the most relevant and up-to-date information regarding current and emerging therapeutic options for advanced RCC.

Upon completion of this activity, participants will be able to:

• Evaluate the most current data on established therapies for the treatment of advanced renal cell carcinoma (RCC)
• Analyze the latest efficacy and safety data regarding emerging therapies for the management of advanced RCC
• Propose algorithms for the integration of new data utilizing available and emerging therapies for the treatment of individual patients with advanced RCC

Target Audience

This activity has been designed to meet the educational needs of oncologists, urologists, advanced practice oncology nurses, and other clinicians involved in the management of patients with kidney cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: July 20, 2012 - July 19, 2013
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Robert J. Motzer, MD
Professor of Medicine
Weill Medical College of Cornell University
Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Robert J. Motzer, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Pfizer Inc.

Grant/Research Support from AVEO Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Interviewees

Robert Figlin, MD, FACP
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Associate Director, Academic Programs
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Health Systems
Los Angeles, California

Robert Figlin, MD, FACP, has a financial interest/relationship or affiliation in the form of:

Consultant for Argos Therapeutics; AVEO Pharmaceuticals, Inc.; Bristol-Myers Squibb; Exelixis, Inc.; and Prometheus Laboratories Inc.

Grant/Research Support from Bristol-Myers Squibb.

Toni K. Choueiri, MD
Director, Kidney Cancer Center
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Toni K. Choueiri, MD, has a financial interest/relationship or affiliation in the form of:

Grant/Research Support from Pfizer Inc.

Advisory Board for AVEO Pharmaceuticals, Inc.; Bayer Corporation; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Onyx and Pfizer Inc.

Medical Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Sponsorship, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5127-12-T.

Nurses

IAHB is an approved provider of continuing nursing education by the Utah Nurses Association, an accredited Approver by the American Nurses Credentialing Center’s Commission on Accreditation. (UNA = 0.5 CEH's. Provider Code P09-03).

Note: Not all state nursing boards will accept programs less than 1.0 hour in length for credit. Please click here to find out the status of your state.

This CME/CNE activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education; the activity is also co-provided by the Institute for Advancement of Human Behavior.

This activity is supported by an educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.